drugset / Trial / NCT00299091

Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients

NCT00299091

Phase 4 Completed 31 enrolled Germans Trias i Pujol Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study on the utility of the modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring) in HIV-infected patients initiating treatment with Sustiva.

Timeline

Start
2006-09
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 200 mg
Subject Efavirenz Other / unclassified 600 mg